MA29312B1 - Derives d'acide 5-phenyl-pentanoique en tant qu'inhibiteurs de metalloproteinase matricielle dans le traitement de l'asthme et d'autres maladies - Google Patents
Derives d'acide 5-phenyl-pentanoique en tant qu'inhibiteurs de metalloproteinase matricielle dans le traitement de l'asthme et d'autres maladiesInfo
- Publication number
- MA29312B1 MA29312B1 MA30155A MA30155A MA29312B1 MA 29312 B1 MA29312 B1 MA 29312B1 MA 30155 A MA30155 A MA 30155A MA 30155 A MA30155 A MA 30155A MA 29312 B1 MA29312 B1 MA 29312B1
- Authority
- MA
- Morocco
- Prior art keywords
- nhc
- nr4r5
- aralkyl
- cycloalkyl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/72—Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS AYANT LA STRUCTURE DE FORMULE (I) DANS LAQUELLE N REPRÉSENTE UN ENTIER DE 1 À 5; R1 REPRÉSENTE ALKYLE, ALCÉNYLE, ALKYNYLE, CYCLOALKYLE, ARYLE, HÉTÉROCYCLYLE, HÉTÉROARYLE, ARALKYLE, ALKOXY, ARYLOXY, ALKENYLOXY OU ALKYNYLOXY FALCUTATIVEMENT SUBSTITUÉS; R2 REPRÉSENTE ALCÉNYLE, ALKYNYLE, ARYLE, HÉTÉROCYCLYLE, HÉTÉROARYLE, CYCLOALKYLE, NR4R5, -NHC(=Y)R4, -NHC(=Y)NR5RX, -NHC(=O)OR4, -NHSO2R4, C(=Y)NR4R5, C(=O)OR6 [OÙ Y REPRÉSENTE OXYGÈNE OU SOUFRE], OR5, -OC(=O)NR4R5, O-ACYLE, S(O)MR4, -SO2N(R4)2, CYANO, AMIDINO OU GUANIDINO [OÙ R4 REPRÉSENTE ALKYLE, ALCÉNYLE, ALKYNYLE, CYCLOALKYLE, ARYLE, HÉTÉROCYCLYLE, HÉTÉROARYLE, ARALKYLE, HÉTÉROARYLALKYLE, HÉTÉROCYCLYLALKYLE OU CYCLOALKYLALKYLE ET M REPRÉSENTE UN ENTIER 0-2; R5 REPRÉSENTE HYDROGÈNE OU R4; RX REPRÉSENTE R4 OU -SO2N(R4)2 ET R6 REPRÉSENTE HYDROGÈNE, ALKYLE, CYCLOALKYLE, ARALKYLE, HÉTÉROARYLALKYLE, HÉTÉROCYCLYLALKYLE OU CYCLOALKYLALKYLE]; R3 REPRÉSENTE HYDROGÈNE, FLUOR, ALKYLE, CYCLOALKYLALKYLE OU ARALKYLE; A REPRÉSENTE OH, OR4, -OC(=O)NR4R5, O-ACYLE, NH2, NR4R5, -NHC(=Y)R4, -NHC(=Y)NR5RX, -NHC(=O)OR4, -NHSO2R4; ET LEURS PROCÉDÉS DE SYNTHÈSE. CETTE INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACOLOGIQUES CONTENANT LES COMPOSÉS DE LA PRÉSENTE INVENTION AINSI QUE DES MÉTHODES DE TRAITEMENT DE L'ASTHME, DE LA POLYARTHRITE RHUMATOÏDE, MPOC, LA RHINITE, L'OSTÉOARTHRITE, LA POLYARTHRITE PSORIOSIQUE, LE PSORIASIS, LA FIBROSE PULMONAIRE, L'INFLAMMATION PULMONAIRE, LE SYNDROME DE DÉTRESSE RESPIRATOIRE AIGU, LA PARODONTITE, LA SCLÉROSE EN PLAQUES, LA GINGIVITE, L'ATHÉROSCLÉROSE, LA PROLIFÉRATION NÉOINTIMALE QUI CONDUIT À LA RESTÉNOSE ET L'INSUFFISANCE CARDIAQUE ISCHÉMIQUE, L'ATTAQUE CÉRÉBRALE, LES MALADIES RÉNALES, LES MÉTASTASE TUMORALES AINSI QUE D'AUTRES TROUBLES INFLAMMATOIRES CARACTÉRISÉS PAR UNE SUREXPRESSION ET UNE SURACTIVATION D'UNE MÉTALLOPROTÉINASE MATRICIELLE, À L'AIDES DES COMPOSÉS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN380DE2005 | 2005-02-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29312B1 true MA29312B1 (fr) | 2008-03-03 |
Family
ID=36591260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30155A MA29312B1 (fr) | 2005-02-22 | 2007-08-22 | Derives d'acide 5-phenyl-pentanoique en tant qu'inhibiteurs de metalloproteinase matricielle dans le traitement de l'asthme et d'autres maladies |
Country Status (33)
Country | Link |
---|---|
US (1) | US8710261B2 (fr) |
EP (1) | EP1856063B1 (fr) |
JP (1) | JP4994247B2 (fr) |
KR (1) | KR101274309B1 (fr) |
CN (1) | CN101151255B (fr) |
AP (1) | AP2413A (fr) |
AT (1) | ATE542804T1 (fr) |
AU (1) | AU2006217615B2 (fr) |
BR (1) | BRPI0607469A2 (fr) |
CA (1) | CA2598518C (fr) |
CR (1) | CR9384A (fr) |
CY (1) | CY1112795T1 (fr) |
DK (1) | DK1856063T3 (fr) |
EA (1) | EA013539B1 (fr) |
ES (1) | ES2381681T3 (fr) |
GE (1) | GEP20094786B (fr) |
HK (1) | HK1115379A1 (fr) |
HR (1) | HRP20120250T1 (fr) |
IL (1) | IL185457A0 (fr) |
MA (1) | MA29312B1 (fr) |
MX (1) | MX2007010185A (fr) |
NI (1) | NI200700220A (fr) |
NO (1) | NO20074648L (fr) |
NZ (1) | NZ560803A (fr) |
PL (1) | PL1856063T3 (fr) |
PT (1) | PT1856063E (fr) |
RS (2) | RS20070374A (fr) |
SI (1) | SI1856063T1 (fr) |
SM (1) | SMAP200700038A (fr) |
TN (1) | TNSN07320A1 (fr) |
UA (1) | UA98292C2 (fr) |
WO (1) | WO2006090235A1 (fr) |
ZA (1) | ZA200707560B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
EP1856063B1 (fr) | 2005-02-22 | 2012-01-25 | Ranbaxy Laboratories Limited | Derives d'acide-phenyl-pentanoique en tant qu'inhibiteurs de metalloproteinase matricielle dans le traitement de l'asthme et d'autres maladies |
ES2397284T3 (es) | 2006-08-22 | 2013-03-06 | Ranbaxy Laboratories Limited | Proceso para preparar inhibidores de la metaloproteinasa de la matriz y auxiliares quirales para los mismos |
AU2013200728B2 (en) * | 2006-08-22 | 2014-12-18 | Sun Pharmaceutical Industries Limited | Matrix metalloproteinase inhibitors |
FR2949463B1 (fr) * | 2009-08-26 | 2011-09-16 | Commissariat Energie Atomique | Inhibiteurs de mmp |
CN103119030A (zh) | 2010-07-30 | 2013-05-22 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
CN103228634A (zh) | 2010-09-24 | 2013-07-31 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
WO2012071516A2 (fr) * | 2010-11-23 | 2012-05-31 | Kci Licensing, Inc. | Dispositifs et procédés pour le diagnostic et le traitement de blessures à l'aide de biomarqueurs |
EP2556832B1 (fr) | 2011-08-12 | 2017-07-19 | Universitätsklinikum Freiburg | Uridine et analogues d'uridine pour le traitement de la bronchopneumopathie chronique obstructive |
GB201322512D0 (en) * | 2013-12-19 | 2014-02-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
AU2015367977B9 (en) * | 2014-12-24 | 2020-02-06 | Lg Chem, Ltd | Biaryl derivative as GPR120 agonist |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5109002A (en) | 1989-09-08 | 1992-04-28 | Du Pont Merck Pharmaceutical Company | Antipsychotic 1-cycloalkylpiperidines |
AU675689B2 (en) | 1992-12-01 | 1997-02-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
US5516789A (en) | 1995-04-12 | 1996-05-14 | Abbott Laboratories | Lipoxygenase and cyclooxygenase inhibiting compounds |
EP0927156A1 (fr) * | 1996-09-04 | 1999-07-07 | Warner-Lambert Company | Acides biphenyl-butyriques et leurs derives, utilises comme inhibiteurs des metalloproteases de matrice |
MY117687A (en) * | 1996-10-31 | 2004-07-31 | Bayer Corp | Substituted 4-biphenyl-4-hydroxybutric acid derivatives as matrix metalloprotease inhibitors |
AU8020398A (en) | 1997-06-10 | 1998-12-30 | Unilever Plc | Method for enhancing the activity of an enzyme, bleach composition, detergent composition and process for inhibiting dye transfer |
US6037361A (en) * | 1998-03-09 | 2000-03-14 | Warner-Lambert Company | Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
WO2000006560A1 (fr) | 1998-07-30 | 2000-02-10 | Warner-Lambert Company | Composes heteroaromatiques tricycliques et leurs derives utilises comme inhibiteurs des metalloproteinases matricielles |
IL143594A0 (en) * | 1998-12-30 | 2002-04-21 | Bayer Ag | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases |
ITRM20010464A1 (it) | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica. |
EP1613319B1 (fr) | 2003-04-10 | 2009-06-03 | Ortho-McNeil Pharmaceuticals, Inc. | Acetamides a substitution phenyle et leur utilisation en tant qu'inhibiteurs de protease |
GB0312654D0 (en) * | 2003-06-03 | 2003-07-09 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0314488D0 (en) | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0321538D0 (en) | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
EP1856063B1 (fr) | 2005-02-22 | 2012-01-25 | Ranbaxy Laboratories Limited | Derives d'acide-phenyl-pentanoique en tant qu'inhibiteurs de metalloproteinase matricielle dans le traitement de l'asthme et d'autres maladies |
-
2006
- 2006-02-21 EP EP06727254A patent/EP1856063B1/fr active Active
- 2006-02-21 UA UAA200709535A patent/UA98292C2/ru unknown
- 2006-02-21 EA EA200701768A patent/EA013539B1/ru not_active IP Right Cessation
- 2006-02-21 SM SM200700038T patent/SMAP200700038A/it unknown
- 2006-02-21 NZ NZ560803A patent/NZ560803A/en not_active IP Right Cessation
- 2006-02-21 MX MX2007010185A patent/MX2007010185A/es active IP Right Grant
- 2006-02-21 PL PL06727254T patent/PL1856063T3/pl unknown
- 2006-02-21 DK DK06727254.2T patent/DK1856063T3/da active
- 2006-02-21 CA CA2598518A patent/CA2598518C/fr not_active Expired - Fee Related
- 2006-02-21 BR BRPI0607469-3A patent/BRPI0607469A2/pt not_active IP Right Cessation
- 2006-02-21 ES ES06727254T patent/ES2381681T3/es active Active
- 2006-02-21 AT AT06727254T patent/ATE542804T1/de active
- 2006-02-21 GE GEAP200610276A patent/GEP20094786B/en unknown
- 2006-02-21 RS RSP-2007/0374A patent/RS20070374A/sr unknown
- 2006-02-21 CN CN2006800101326A patent/CN101151255B/zh not_active Expired - Fee Related
- 2006-02-21 AP AP2007004146A patent/AP2413A/xx active
- 2006-02-21 PT PT06727254T patent/PT1856063E/pt unknown
- 2006-02-21 RS RS20120174A patent/RS52232B/en unknown
- 2006-02-21 AU AU2006217615A patent/AU2006217615B2/en not_active Ceased
- 2006-02-21 JP JP2007555726A patent/JP4994247B2/ja not_active Expired - Fee Related
- 2006-02-21 WO PCT/IB2006/000349 patent/WO2006090235A1/fr active Application Filing
- 2006-02-21 SI SI200631274T patent/SI1856063T1/sl unknown
- 2006-02-21 KR KR1020077021829A patent/KR101274309B1/ko not_active IP Right Cessation
- 2006-02-21 US US11/816,836 patent/US8710261B2/en not_active Expired - Fee Related
-
2007
- 2007-08-21 TN TNP2007000320A patent/TNSN07320A1/en unknown
- 2007-08-22 NI NI200700220A patent/NI200700220A/es unknown
- 2007-08-22 IL IL185457A patent/IL185457A0/en unknown
- 2007-08-22 MA MA30155A patent/MA29312B1/fr unknown
- 2007-09-03 ZA ZA200707560A patent/ZA200707560B/xx unknown
- 2007-09-12 NO NO20074648A patent/NO20074648L/no not_active Application Discontinuation
- 2007-09-14 CR CR9384A patent/CR9384A/es unknown
-
2008
- 2008-05-15 HK HK08105396.1A patent/HK1115379A1/xx not_active IP Right Cessation
-
2012
- 2012-03-19 HR HR20120250T patent/HRP20120250T1/hr unknown
- 2012-04-04 CY CY20121100336T patent/CY1112795T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29312B1 (fr) | Derives d'acide 5-phenyl-pentanoique en tant qu'inhibiteurs de metalloproteinase matricielle dans le traitement de l'asthme et d'autres maladies | |
US5508273A (en) | Substituted phosphonic acids and derivatives useful in treating bone wasting diseases | |
AR063945A1 (es) | Acidos carboxilicos inhibidores de la metalproteinasa matriz. | |
TN2009000138A1 (fr) | Biaryl-ether-urees | |
Chand et al. | Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives | |
JP2010538019A5 (fr) | ||
US9963472B2 (en) | Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (PKAN) and methods for the synthesis of such compounds | |
JPH0291052A (ja) | 置換アミン類 | |
BG105745A (en) | 2,3-o-isopropylidene derivatives of monosaccharides as cell adhesion inhibitors | |
Chang et al. | New asparagine analogs | |
Shang et al. | Development of 3, 5-dinitrobenzoate-based 5-lipoxygenase inhibitors | |
Barnden et al. | 763. Some preparative uses of benzylpenicillinic ethoxyformic anhydride | |
EP0219468B1 (fr) | Dérivé de l'acide 4-méthoxyisophtalique ayant une activité pharmacologique contre les maladies thrombo-emboliques et procédé de préparation dudit composé | |
Adediran et al. | Substituted aryl malonamates as new serine β-lactamase substrates: Structure–activity studies | |
CN110194731B (zh) | 巯基丙酰胺类化合物及其制备方法和药用用途 | |
WO2022003377A1 (fr) | Thiéno[3,4-c]pyrazol-3-yl acétamides utilisés en tant qu'inhibiteurs de l'autotaxine | |
EP0070131A1 (fr) | Acides phosphonoalcanoylamino | |
Zhang et al. | Synthesis, antiproliferation, and docking studies of N-phenyl-lipoamide and 8-mercapto-N-phenyloctanamide derivatives: effects of C6 position thiol moiety | |
TH96596B (th) | ตัวยับยั้งปฏิกิริยาเมตริกซ์เมทัลโลโปรตีเนส | |
WO2007035964A2 (fr) | Bioisoteres de la vigabatrine et methodes d'utilisation de ceux-ci | |
Cheng et al. | The Synthesis of β-Aminoethyl Ketones as Potential Antagonists of β-Alanine | |
US9682929B2 (en) | Metalloprotease inhibitors, methods for producing same, and therapeutics uses thereof | |
TH96596A (th) | ตัวยับยั้งปฏิกิริยาเมตริกซ์เมทัลโลโปรตีเนส | |
JPH05238935A (ja) | オピオイド分解酵素阻害剤 | |
US20190211005A1 (en) | Aryl-2,2'-tandem bisthiazole compound and preparation method and use thereof |